CYP3A isoforms in Ewing's sarcoma tumours: An immunohistochemical study with clinical correlation

International Journal of Experimental Pathology

Volumn 96, Issue 2, 2015, Pages 81-86

  Zia, Hamid ^a   Murray, Graeme I ^b   Vyhlidal, Carrie A ^c   Leeder, J Steven ^c   Anwar, Ahmed E ^d   Bui, Marilyn M ^e   Ahmed, Atif A ^c  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CYP3A4; Cytochrome p450; Ewing's sarcoma; Immunohistochemistry

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; ISOPROTEIN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYP3A7 PROTEIN, HUMAN; CYTOCHROME P450 3A; TUMOR MARKER; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EWING SARCOMA; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR VOLUME; BONE TUMOR; DISEASE COURSE; LONGITUDINAL STUDY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, TUMOR; BONE NEOPLASMS; CHILD; CYTOCHROME P-450 CYP3A; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN ISOFORMS; SARCOMA, EWING; SURVIVAL RATE; YOUNG ADULT;

EID: 84929948634     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12115     Document Type: Article

References (36)

1. Ahmed A., Zia H. & Wagner L. (2014) Therapy resistance mechanisms in Ewing's sarcoma family tumors. Cancer Chemother. Pharmacol. 73, 657-663.
2. Arvand A. & Denny C.T. (2001) Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20, 5747-54.
3. Burk O. & Wojnowski L. (2004) Cytochrome P450 3A and their regulation. Naunyn-Schmiedebergs Arch. Pharmacol. 369, 105-24.
4. Carvajal R. & Meyers P. (2005) Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol. Oncol. Clin. North Am. 19, 501-25.
5. Choi E.Y., Gardner J.M., Lucas D.R., McHugh J.B. & Patel R.M. (2014) Ewing sarcoma. Semin. Diagn. Pathol. 31, 39-47.
6. Dhaini H.R., Thomas D.G., Giordano T.J. et al. (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 21, 2481-5.
7. Grier H.E. (1997) The Ewing's family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr. Clin. North Am. 44, 991-1004.
8. Haas S., Pierl C., Harth V. et al. (2006) Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int. J. Cancer 119, 1785-91.
9. Hakkola J., Raunio H., Purkunen R. et al. (2001) Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate 80, 193-201.
10. Hughes S.J., Morse M.A., Weghorst C.M. et al. (1999) Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia. Neoplasia 1, 145-53.
11. Kissane J.M., Askin F.B., Foulkes M., Stratton L.B. & Shirley S.F. (1983) Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum. Pathol. 14, 773-9.
12. Kuehl P., Zhang J., Lin Y. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-91.
13. Kumarakulasingham M., Rooney P.H., Dundas S.R. et al. (2005) Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 11, 3758-65.
14. Leeder J.S., Gaedigk R., Marcucci K.A. et al. (2005) Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 314, 626-35.
15. McFadyen M.C., Melvin W.T. & Murray G.I. (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. 3, 363-71.
16. Murray G.I. (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J. Pathol. 192, 419-26.
17. Murray G.I., Barnes T.S., Sewell H.F. et al. (1987) Cytochrome P-450 localization in normal human adult and foetal liver by immunocytochemistry using a monoclonal antibody against human cytochrome P-450. Histochem. J. 19, 537-45.
18. Murray G.I., Barnes T.S., Sewell H.F., Ewen S.W., Melvin W.T. & Burke M.D. (1988) The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br. J. Clin. Pharmacol. 25, 465-75.
19. Murray G.I., McKay J.A., Weaver R.J., Ewen S.W., Melvin W.T. & Burke M.D. (1993) Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J. Pathol. 171, 49-52.
20. Murray G.I., McFadyen M.C., Mitchell R.T., Cheung Y.L., Kerr A.C. & Melvin W.T. (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br. J. Cancer 79, 1836-42.
21. Murray G.I., Patimalla S., Stewart K.N., Miller I.D., Heys S.D. (2010) Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57, 202-11.
22. Ortiz de Montellano P.R. (2013) Cytochrome P450-activated prodrugs. Future Med. Chem. 5, 213-28.
23. Panigrahy D., Kaipainen A., Greene E.R. & Huang S. (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 29, 723-35.
24. Patterson L.H. & Murray G.I. (2002) Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8, 1335-47.
25. Patterson L.H., McKeown S.R., Robson T., Gallagher R., Raleigh S.M. & Orr S. (1999) Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 14, 473-86.
26. Pinkerton C.R., Bataillard A., Guillo S., Oberlin O., Fervers B. & Philip T. (2001) Treatment strategies for metastatic Ewing's sarcoma. Eur. J. Cancer 37, 1338-44.
27. Pinto A., Dickman P. & Parham D. (2011) Pathobiologic markers of the Ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma 2011, 1-15.
28. Raleigh S.M., Wanogho E., Burke M.D. & Patterson L.H. (1999) Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica 29, 1115-22.
29. Rodriguez-Antona C. & Ingelman-Sundberg M. (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25, 1679-91.
30. van Schaik R.H. (2005) Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest. New Drugs 23, 513-22.
31. Schlauder S.M., Steffensen T.S., Morgan M. et al. (2008) Assessment of muscarinic and nicotinic acetylcholine receptor expression in primitive neuroectodermal tumor/Ewing family of tumor and desmoplastic small round cell tumor: an immunohistochemical and western blot study of tissue microarray and cell lines. Fetal Pediatr. Pathol. 27, 83-97.
32. Scotlandi K., Remondini D., Castellani G. et al. (2009) Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J. Clin. Oncol. 27, 2209-16.
33. Sim S.C., Edwards R.J., Boobis A.R. & Ingelman-Sundberg M. (2005) CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet. Genomics 15, 625-31.
34. Tayeb M.T., Clark C., Haites N.E., Sharp L., Murray G.I. & McLeod H.L. (2003) CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 88, 928-32.
35. de Wildt S.N., Kearns G.L., Leeder J.S. & van den Anker J.N. (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485-505.
36. Zordoky B.N. & El-Kadi A.O. (2009) Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab. 10, 164-78.